These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 30632143)

  • 1. Treating Alzheimer's disease by targeting iron.
    Nikseresht S; Bush AI; Ayton S
    Br J Pharmacol; 2019 Sep; 176(18):3622-3635. PubMed ID: 30632143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A short perspective on the long road to effective treatments for Alzheimer's disease.
    Reynolds DS
    Br J Pharmacol; 2019 Sep; 176(18):3636-3648. PubMed ID: 30657599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutics for dementia and Alzheimer's disease: New directions for precision medicine.
    Duce JA; Zhu X; Jacobson LH; Beart PM
    Br J Pharmacol; 2019 Sep; 176(18):3409-3412. PubMed ID: 31468515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy.
    Nalivaeva NN; Turner AJ
    Br J Pharmacol; 2019 Sep; 176(18):3447-3463. PubMed ID: 30710367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Br J Pharmacol; 2016 Jul; 173(13):2080-94. PubMed ID: 26332830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Don't forget astrocytes when targeting Alzheimer's disease.
    Sadick JS; Liddelow SA
    Br J Pharmacol; 2019 Sep; 176(18):3585-3598. PubMed ID: 30636042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The involvement of microglia in Alzheimer's disease: a new dog in the fight.
    Moore Z; Taylor JM; Crack PJ
    Br J Pharmacol; 2019 Sep; 176(18):3533-3543. PubMed ID: 30445661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease.
    Lopez Sanchez MIG; van Wijngaarden P; Trounce IA
    Br J Pharmacol; 2019 Sep; 176(18):3464-3474. PubMed ID: 30471088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.
    Perez Ortiz JM; Swerdlow RH
    Br J Pharmacol; 2019 Sep; 176(18):3489-3507. PubMed ID: 30675901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease.
    Fitz NF; Nam KN; Koldamova R; Lefterov I
    Br J Pharmacol; 2019 Sep; 176(18):3599-3610. PubMed ID: 30924124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues.
    Ittner LM; Klugmann M; Ke YD
    Br J Pharmacol; 2019 Sep; 176(18):3649-3665. PubMed ID: 30817847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets.
    Nizami S; Hall-Roberts H; Warrier S; Cowley SA; Di Daniel E
    Br J Pharmacol; 2019 Sep; 176(18):3515-3532. PubMed ID: 30740661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The essential elements of Alzheimer's disease.
    Lei P; Ayton S; Bush AI
    J Biol Chem; 2021; 296():100105. PubMed ID: 33219130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferroptosis: a potential therapeutic target for Alzheimer's disease.
    Yang L; Nao J
    Rev Neurosci; 2023 Jul; 34(5):573-598. PubMed ID: 36514247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron and Ferroptosis as Therapeutic Targets in Alzheimer's Disease.
    Gleason A; Bush AI
    Neurotherapeutics; 2021 Jan; 18(1):252-264. PubMed ID: 33111259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective.
    Derry PJ; Hegde ML; Jackson GR; Kayed R; Tour JM; Tsai AL; Kent TA
    Prog Neurobiol; 2020 Jan; 184():101716. PubMed ID: 31604111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteostasis network provides targets for neurodegeneration.
    Newton TM; Duce JA; Bayle ED
    Br J Pharmacol; 2019 Sep; 176(18):3508-3514. PubMed ID: 30820936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipose tissue as a therapeutic target for vascular damage in Alzheimer's disease.
    Bettinetti-Luque M; Trujillo-Estrada L; Garcia-Fuentes E; Andreo-Lopez J; Sanchez-Varo R; Garrido-Sánchez L; Gómez-Mediavilla Á; López MG; Garcia-Caballero M; Gutierrez A; Baglietto-Vargas D
    Br J Pharmacol; 2024 Mar; 181(6):840-878. PubMed ID: 37706346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of oligomeric amyloid β peptide binding to α7 nicotinic receptor.
    Cecon E; Dam J; Luka M; Gautier C; Chollet AM; Delagrange P; Danober L; Jockers R
    Br J Pharmacol; 2019 Sep; 176(18):3475-3488. PubMed ID: 30981214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline.
    Semerano A; Fernández-Ruiz J; Cortes-Canteli M; Moro MA
    Br J Pharmacol; 2024 Mar; 181(6):755-759. PubMed ID: 38204183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.